Ask My Investor AI
Private companyPublished company research
PRIVATE

Official Curium materials identify a Boston-headquartered, privately controlled global nuclear-medicine company. The November 2025 announcement says CapVest would remain controlling shareholder after a continuation-vehicle recapitalization expected to close in Q1 2026; closing confirmation was not located in this pass.

Curium

Curium is a private nuclear-medicine pure-play with an official footprint of more than 14 million patients annually, 6,000-plus customers, more than 5,000 employees, one molybdenum-processing plant, four manufacturing sites, 44 radiopharmacies and 50 products. Its vertically integrated diagnostic and therapeutic network is directly in-theme. The announced continuation vehicle valued Curium at about $7B, but public operating statements, a public security and current licensed valuation are unavailable, so the subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
private
Ticker
None
Exchange
None
HQ
United States
Currency
n/a
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

Curium combines isotope processing, regulated manufacturing, radiopharmacies, time-critical logistics and market access across more than 60 countries. That vertical integration and network density are meaningful barriers. Official operating scale is clear, but revenue, margins, leverage, capacity utilization and product economics are not publicly disclosed.

Scarce assets

One molybdenum-processing plant, four manufacturing sites, 44 radiopharmacies, regulated product approvals, a more-than-50-product portfolio, short-half-life logistics and a global customer network.

Products, segments, and customers

The company develops, manufactures and distributes diagnostic and therapeutic radiopharmaceuticals, including Mo-99/Tc-99m-linked products, PET/SPECT diagnostics and radioligand-therapy programs. Public segment financial reporting is unavailable.

Theme capture

Curium is definitionally a 100%-focused nuclear-medicine operator, so product capability and thematic exposure are direct. Financial magnitude cannot be evaluated from public operating data, and no listed Curium security is available.

Conditions

What must be true

  1. The integrated network must translate scale into reliable supply, attractive utilization and durable margins.
  2. The announced recapitalization must close on terms that preserve sufficient capital for pipeline and capacity investment.
  3. Therapeutic expansion must complement rather than destabilize the established diagnostics and distribution base.

Identifiable catalysts

  • Confirmation of the announced continuation-vehicle transaction closing.
  • New diagnostic and radioligand-therapy launches.
  • Capacity investment, partnership or financing disclosures that reveal operating economics.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Vertically integrated radiopharmaceutical development, isotope processing, manufacturing, radiopharmacy distribution and emerging therapeutics.

Medical isotopes and radiopharmaceutical logistics

Direct, definitionally material operating exposure. Curium states that it is 100% focused on nuclear medicine and serves more than 14 million patients annually through one molybdenum-processing plant, four manufacturing sites, 44 radiopharmacies and a portfolio of 50 products.

Evidence
Official corporate pages support the footprint and focus. The November 2025 transaction announcement values the private company at about $7B but provides no public revenue, margin, leverage or utilization data.
Materiality
disclosed — The issuer describes 100% focus on nuclear medicine, so thematic operating exposure is definitional; financial quality and current valuation remain unassessed because the company is private and does not publish operating statements.
Financial evidence

Official public disclosures

Reference period: 2025-2026 corporate disclosures.

  • Announced continuation-vehicle valuationapproximately $7B; announced, subject to closing
    November 2025[3]
  • Patients servedmore than 14M annually
    current corporate disclosure[1]
  • Operating footprint1 molybdenum-processing plant, 4 manufacturing sites, 44 radiopharmacies and 50 products
    current corporate disclosure[1]

Limitation: The roughly $7B figure is an announced private transaction value, not licensed current market valuation. Curium publishes no reusable revenue, earnings, cash-flow, leverage, utilization or product-margin statements.

Risks

Material risks and break conditions

Material risks

  • Private ownership and absent public financial statements prevent assessment of leverage, cash generation and return on invested capital.
  • Short-half-life manufacturing and distribution carry regulatory, quality, reactor-supply and logistics risk.
  • Therapeutic pipeline investment may require substantial capital before commercial returns are visible.

Thesis-break conditions

  • The announced recapitalization does not close or materially constrains future investment.
  • Public disclosures show sustained supply, quality or regulatory failures across the integrated network.
  • Therapeutic launches fail while diagnostics volumes or pricing deteriorate.
Investability conclusion

Where the evidence lands

NOT_READY and not directly investable through a public security. Official sources establish private identity, pure-play exposure, network scale and the announced approximately $7B recapitalization value. Public operating economics, current licensed valuation and human reviewer acceptance are absent.

Next diligence

  1. Confirm completion and final terms of the announced recapitalization.
  2. Obtain audited revenue, EBITDA, leverage, utilization and product-mix evidence if it becomes publicly available.
  3. Track Curium as a private competitive benchmark rather than a listed investment candidate.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Curium: who we areCurium · primary · published 2026-07-29 · accessed 2026-07-29
  2. Curium: how we workCurium · primary · published 2026-07-29 · accessed 2026-07-29
  3. CapVest recapitalizes Curium to accelerate its growth strategyCurium · primary · published 2025-11-20 · accessed 2026-07-29